FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a monoclonal antibody or antibody fragment comprising an antigen-binding portion thereof which binds to a phospholipase D4 (PLD4) protein, as well as use thereof for treating or preventing a disease caused by activated B-cells, for suppressing activated B-cells, as well as for treating a disease caused by activated B-cells. Also disclosed is a method of detecting activated B-cells, as well as a reagent for detecting activated B-cells, containing said antibody or fragment thereof. Invention also relates to an in vitro method of suppressing activated B-cells, involving use of the antibody binding to PLD4, or its fragment.
EFFECT: invention enables effective treatment or prevention of the disease caused by activated B-cells.
16 cl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| MONOCLONAL ANTIBODIES BINDING WITH hGM-CSF AND COMPOSITIONS FOR MEDICINAL PURPOSES, CONTAINING THEREOF | 2008 |
|
RU2517596C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
